Skip to main content

Table 1 Patient Baseline Characteristics. The baseline demographics and clinical characteristics of patients with advanced EGFRm+ NSCLC treated with first-line afatinib (n = 125) in our cohort

From: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

Characteristic No. %
Sex
 Male 64 51.2
 Female 61 48.8
Age at diagnosis, years
 Median 62
 Range 26–86
Ethnicity
 Chinese 100 80.0
 Malay 14 11.2
 Indian 3 2.4
 Others 8 6.4
Smoking status
 Never 95 76.0
 Former 17 13.6
 Current 13 10.4
Histotype – NSCLC
 Adenocarcinoma 121 96.8
 Adenosquamous carcinoma 1 0.8
 NOS 3 2.4
EGFR mutation type
 Exon 19 deletion[a] 87 69.6
 Exon 21 L858R 27 21.6
 Others[b] 11 8.8
Brain metastases at baseline
 No 82 65.6
 Yes 42 33.6
 Unknown 1 0.8
Starting dose of afatinib once daily (OD)
 40 mg 62 49.6
 0 mg 61 48.8
 0 mg 1 0.8
 Unknown 1 0.8
  1. [a]E746_A750del; E746_A750delinsIP; E746_A750delinsQP; E746_A750delinsVP; E746_T751delinsV; E746_S752delinsV; E746_P753delinsVS; L747_A750delinsP; L747_T751del; L747_P753delinsS; NOS
  2. [b]E697Q; A763_Y764insFQEA; Double mutation; Unknown
  3. NSCLC Non-small cell lung cancer, NOS Not otherwise specified